Bradley J Ahrens1,2,3, Lin Li1, Alexandra K Ciminera3,4, Junie Chea1, Erasmus Poku1, James R Bading5, Michael R Weist1,3, Marcia M Miller6, David M Colcher1, John E Shively7. 1. Deparment of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California. 2. Division of Comparative Medicine, Beckman Research Institute of the City of Hope, Duarte, California. 3. Irell and Manella Graduate School of Biological Sciences, City of Hope, Duarte, California. 4. Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California. 5. Department of Medical Oncology, City of Hope, Duarte, California; and. 6. Department of Cell and Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, California. 7. Deparment of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California jshively@coh.org.
Abstract
The development of improved breast cancer screening methods is hindered by a lack of cancer-specific imaging agents and effective small-animal models to test them. The purpose of this study was to evaluate 64Cu-DOTA-alendronate as a mammary microcalcification-targeting PET imaging agent, using an ideal rat model. Our long-term goal is to develop 64Cu-DOTA-alendronate for the detection and noninvasive differentiation of malignant versus benign breast tumors with PET. Methods: DOTA-alendronate was synthesized, radiolabeled with 64Cu, and administered to normal or tumor-bearing aged, female, retired breeder Sprague-Dawley rats for PET imaging. Mammary tissues were subsequently labeled and imaged with light, confocal, and electron microscopy to verify microcalcification targeting specificity of DOTA-alendronate and elucidate the histologic and ultrastructural characteristics of the microcalcifications in different mammary tumor types. Tumor uptake, biodistribution, and dosimetry studies were performed to evaluate the efficacy and safety of 64Cu-DOTA-alendronate. Results: 64Cu-DOTA-alendronate was radiolabeled with a 98% yield. PET imaging using aged, female, retired breeder rats showed specific binding of 64Cu-DOTA-alendronate in mammary glands and mammary tumors. The highest uptake of 64Cu-DOTA-alendronate was in malignant tumors and the lowest uptake in benign tumors and normal mammary tissue. Confocal analysis with carboxyfluorescein-alendronate confirmed the microcalcification binding specificity of alendronate derivatives. Biodistribution studies revealed tissue alendronate concentrations peaking within the first hour, then decreasing over the next 48 h. Our dosimetric analysis demonstrated a 64Cu effective dose within the acceptable range for clinical PET imaging agents and the potential for translation into human patients. Conclusion: 64Cu-DOTA-alendronate is a promising PET imaging agent for the sensitive and specific detection of mammary tumors as well as the differentiation of malignant versus benign tumors based on absolute labeling uptake.
The development of improved breast cancer screening methods is hindered by a lack of cancer-specific imaging agents and effective small-animal models to test them. The purpose of this study was to evaluate 64Cu-DOTA-alendronate as a mammary microcalcification-targeting PET imaging agent, using an ideal rat model. Our long-term goal is to develop 64Cu-DOTA-alendronate for the detection and noninvasive differentiation of malignant versus benign breast tumors with PET. Methods:DOTA-alendronate was synthesized, radiolabeled with 64Cu, and administered to normal or tumor-bearing aged, female, retired breeder Sprague-Dawley rats for PET imaging. Mammary tissues were subsequently labeled and imaged with light, confocal, and electron microscopy to verify microcalcification targeting specificity of DOTA-alendronate and elucidate the histologic and ultrastructural characteristics of the microcalcifications in different mammary tumor types. Tumor uptake, biodistribution, and dosimetry studies were performed to evaluate the efficacy and safety of 64Cu-DOTA-alendronate. Results:64Cu-DOTA-alendronate was radiolabeled with a 98% yield. PET imaging using aged, female, retired breeder rats showed specific binding of 64Cu-DOTA-alendronate in mammary glands and mammary tumors. The highest uptake of 64Cu-DOTA-alendronate was in malignant tumors and the lowest uptake in benign tumors and normal mammary tissue. Confocal analysis with carboxyfluorescein-alendronate confirmed the microcalcification binding specificity of alendronate derivatives. Biodistribution studies revealed tissue alendronate concentrations peaking within the first hour, then decreasing over the next 48 h. Our dosimetric analysis demonstrated a 64Cu effective dose within the acceptable range for clinical PET imaging agents and the potential for translation into humanpatients. Conclusion:64Cu-DOTA-alendronate is a promising PET imaging agent for the sensitive and specific detection of mammary tumors as well as the differentiation of malignant versus benign tumors based on absolute labeling uptake.
Authors: Joanne E Mortimer; James R Bading; David M Colcher; Peter S Conti; Paul H Frankel; Mary I Carroll; Shan Tong; Erasmus Poku; Joshua K Miles; John E Shively; Andrew A Raubitschek Journal: J Nucl Med Date: 2013-12-12 Impact factor: 10.057
Authors: V Cocquyt; W F Kline; B J Gertz; S J Van Belle; S D Holland; M DeSmet; H Quan; K P Vyas; K E Zhang; J De Grève; A G Porras Journal: J Clin Pharmacol Date: 1999-04 Impact factor: 3.126
Authors: Debbie Saslow; Judy Hannan; Janet Osuch; Marianne H Alciati; Cornelia Baines; Mary Barton; Janet Kay Bobo; Cathy Coleman; Mary Dolan; Ginny Gaumer; Daniel Kopans; Susan Kutner; Dorothy S Lane; Herschel Lawson; Helen Meissner; Candace Moorman; Henry Pennypacker; Peggy Pierce; Eva Sciandra; Robert Smith; Ralph Coates Journal: CA Cancer J Clin Date: 2004 Nov-Dec Impact factor: 508.702
Authors: Lin Li; James Bading; Paul J Yazaki; Amitkumar H Ahuja; Desiree Crow; David Colcher; Lawrence E Williams; Jeffrey Y C Wong; Andrew Raubitschek; John E Shively Journal: Bioconjug Chem Date: 2007-11-08 Impact factor: 4.774
Authors: George P Keeling; Billie Sherin; Jana Kim; Belinda San Juan; Tilmann Grus; Thomas R Eykyn; Frank Rösch; Gareth E Smith; Philip J Blower; Samantha Y A Terry; Rafael T M de Rosales Journal: Bioconjug Chem Date: 2020-08-27 Impact factor: 4.774